ArticlePLoS biology2026
Dose-dependent activation of the Hippo pathway by Type I and Type III interferons suppresses tissue repair by human bronchial epithelial cells.
Article in PLoS biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hippo signalling as a nexus in host-virus interactions.PLoS pathogens · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Interferons (IFNs) are potent antiviral cytokines that are rapidly activated when infected cells sense a virus, but continued IFN production following acute infection is linked to impaired recovery. IFNs protect against infection by inducing a suite of antiviral effectors in IFN receptor-expressing cells via JAK/STAT signaling. However, how IFNs curtail tissue repair is not fully understood. Here, we studied the effects of Type III IFNs (IFNλ1 and IFNλ2) and Type I IFN (IFNβ) on tissue repair functions of human bronchial epithelial cells (HBEC). We show that both Type III IFNs and IFNβ reduce bronchial epithelial cell migration and proliferation through a common upstream mechanism: activation of LATS1, a kinase best known for limiting organ growth as part of the Hippo signaling pathway. Mechanistically, Type III IFN or IFNβ curtailed wound healing by triggering phosphorylation of LATS1 via JAK activity, bypassing activation of MST1/2, the canonical activator of LATS1 in the Hippo pathway. Further experiments showed that distinct signaling pathways lead to LATS1 and STAT1 phosphorylation downstream of IFN receptor signaling. STAT1 was dispensable for IFN-mediated LATS1 phosphorylation and suppression of tissue repair, although as expected STAT1 was required for IFN-mediated protection from rhinovirus or influenza infection. Dose-response curve experiments revealed that higher concentrations of IFN were required to trigger LATS1 phosphorylation compared to STAT1 phosphorylation. Consistently, during rhinovirus or influenza virus infection of organotypic HBEC cultures, we observed phosphorylation of both LATS1 and STAT1, but with different kinetics, with LATS1 activation showing earlier resolution compared to STAT1 activation. These results provide a conceptual framework for understanding how IFN receptor signaling differentially controls epithelial functions required for tissue repair and antiviral defense, and inform efforts to target pathological effects of IFNs following viral infection and in other high IFN states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.